SCHEMBL4030744

SCHEMBL4030744

Nc1ccc(C(=O)NCC(=O)O)cc1-c1nnn[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
MAPT P10636 1/20 0.47
HIF1A Q16665 1/20 0.47
SLC22A6 Q4U2R8 1/20 0.47
SLC22A8 Q8TCC7 1/20 0.47
PTPRC P08575 2/20 0.45
CTSL P07711 1/20 0.45
PTPN13 Q12923 1/20 0.45
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
MAPK1 P28482 1/20 0.40
ATM Q13315 1/20 0.36
BTK Q06187 1/20 0.35
CA9 Q16790 1/20 0.35
USP5 P45974 1/20 0.35
HPGD P15428 2/20 0.34
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4022857 0.82 THRB (0.39) CA2HPGDSMN1; SMN2
SCHEMBL4029711 0.76 PIN1 (0.35) ITGB3ITGA2B
SCHEMBL4026769 0.74 MAPT (0.36) MAPTHPGDALDH1A1SMN1; SMN2F2
SCHEMBL4021504 0.74 HPGD (0.42) MAPTHPGDALDH1A1SMN1; SMN2
SCHEMBL4025972 0.74 TERT (0.36) TERT
SCHEMBL4029705 0.74 KDM4E (0.45) KDM4EMAPTHIF1ASLC22A6SLC22A8
SCHEMBL1463345 0.74 EPHX2 (0.39) MAPTPTPRCCTSLPTPN13
SCHEMBL4026720 0.73 JAK2 (0.51) MAPTCA2CA9SMN1; SMN2
SCHEMBL4025859 0.72 MKNK1 (0.44)
SCHEMBL4024368 0.71 HPGD (0.45) KDM4ECA1CA2BTKCA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537075-B1 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH AS (DK) 2009-07-01 EP disclosed
CN-100497302-C Diarylurea derivatives and their use as chloride channel blockers NEUROSEARCH AS (DK) 2009-06-10 CN disclosed
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers NEUROSEARCH A/S (DK) 2006-07-20 US disclosed
CN-1678573-A Diaryl urea derivatives and their use as chlorine channel blockers NEUROSEARCH AS (DK) 2005-10-05 CN disclosed
EP-1537075-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2005-06-08 EP disclosed
WO-2004022529-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160856-A1 Diarylurea derivatives and their use as chloride channel blockers KIT, ORAI1, CACNA1C KDM4E 1042/4885MAPT 4510/4885HIF1A 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.